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Summary
The etiology of irritable bowel syndrome (IBS) and dysmotil-
ity has not been well-established. Organic, pathognomic changes 
have not been described. Recently, Ohlsson et al
1 suggested that 
higher levels of gonadotropin-releasing hormone (GnRH) IgM 
antibodies in serum were detected in patients with IBS and dys-
motility, but not in organic gastrointestinal (GI) diseases, com-
pared with healthy controls. They evaluated the presence of IgM 
and IgG antibodies against GnRH in serum using an ELISA 
method from healthy subjects and patients with GI diseases. The 
prevalence of GnRH IgM antibodies were higher in IBS and 
dysmotility patients than those in healthy controls (42% vs 23%, 
P = 0.008), and the expressed levels were higher (P = 0.000). 
Patients with celiac disease or inflammatory bowel disease had the 
same or lower levels of antibodies. 
The authors concluded that antibodies against GnRH were 
common in patients with IBS and dysmotility, but not in organic 
diseases, compared with healthy controls, which might explain 
the symptoms in a subgroup of patients with these diseases. 
These findings suggested that IBS and dysmotility to some extent 
might be of an autoimmune origin.
Comment
IBS is a chronic functional GI disorder characterized by epi-
sodic abdominal pain or discomfort in association with altered 
bowel habits. The pathophysiology is poorly understood, there 
are no disease-specific biomarkers, and diagnosis depends solely 
on symptom-based criteria. A variety of factors are believed to 
play a role in the development of the IBS symptoms including al-
tered bowel motility, visceral hypersensitivity, psychosocial stres-
sors, altered brain-gut interactions, low grade inflammation, al-
teration in the gut microbiome and genetic factors.
2 Gastrointes-
tinal motility requires coordination between the intrinsic and the 
extrinsic nervous system, the interstitial cells of Cajal and smooth 
muscle cells.
3 The etiology of dysmotility has been suggested as 
autoimmunity or inflammation, although it is unknown in most 
cases.
4 The concept that inflammation plays a role in IBS has 
raised interest in the immune system as a source of biological 
markers for this condition.
5 Recently, high-sensitivity C-reactive 
protein levels of serum had been higher in IBS patients than 
healthy controls. This might reflect that the low-gut inflamma-
tion is believed to occur in IBS and support its existence. But the 
blood levels were still in the normal laboratory ranges.
6 A small 
portion of patients with inflammatory enteric neuropathy includ-Autoimmune Origin on IBS and Dysmotility
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ing IBS, had antibodies directed towards neuronal ion channels 
in immunochemical analysis of full-thickness jejunal laparoscopic 
biopsies.
7 Only 2 of 33 patients, both with IBS, were found to 
have positive antibody titers. One had autobodies to volt-
age-gated potassium channels and one had antibodies to α3-ace-
tylcholine receptor.
7 And the prevalence of serum neural auto-
antibodies with IBS did not differ significantly from controls.
8 To 
date, the specific blood parameter for IBS has not been identified.
Lembo et al
9 reported that complex patterns of the serum 
concentration among 10 biomarkers were identified that best sep-
arated IBS from non-IBS in a training cohort of patients (n = 
1,205) using the Smart Diagnostic Algorithm. The sensitivity 
and specificity of the 10-biomarker algorithm for differentiating 
IBS from non-IBS was 50% and 88% respectively. The positive 
predictive value was 81%, and the negative predictive value was 
64% at 50% IBS prevalence in the validation cohort. But the bio-
markers were not directly involved in the IBS pathophysiology.
The main finding in the present study was the prevalence of 
higher levels of GnRH IgM antibodies in patients with idio-
pathic GI complaints in the form of IBS or dysmotility. There 
was no correlation to the presence of these antibodies and any lab-
oratory analyses or other co-existing diseases. The GnRH and its 
receptor were present in the human enteric nervous system 
(ENS).
4,10 The GnRH effect on the ENS is not completely eval-
uated, but GnRH has been shown to stimulate motor function in 
the GI tract in female rats,
11 and to stimulate motor function in a 
patient suffering from chronic intestinal pseudo-obstruction.
12 
Antibodies against GnRH and reduced amount of GnRH con-
taining neurons in the ENS have sporadically been found in pa-
tients suffering from IBS.
4 The antibodies may be secondary to 
damage of the ENS exposing GnRH to immune-reactive cells, 
eg, mast cells, resulting in neuronal degeneration.
13 But, little is 
known about the relation in the development of the antibodies 
and any dysmotility symptoms, yet. Although the role of GnRH 
antibodies is not fully understood, there is a possibility that the 
antibodies may be a kind of functional antibody in pathophysiol-
ogy of motility disorder.
In present study, antibodies against GnRH are the first ob-
jective specific blood parameters found so far. But this study con-
sidered all antibody levels above 0 as positive expression, and if a 
higher baseline of antibodies present in serum had been regarded 
as positive expression, almost all controls would have been below 
this level. Therefore, the cut off level for positive expression of 
GnRH IgM antibodies should be investigated. In spite of this 
limitation, this article has provided an interesting insight into an 
autoimmunity in pathogenesis of IBS and dysmotility in dis-
tinction from various autoimmune response with IBD and celiac 
disease. The physiologic and pathophysiologic role of GnRH on 
GI functions deserves further study.
References
1. Ohlsson B, Sjöberg K, Alm R, Fredrikson GN. Patients with irrita-
ble bowel syndrome and dysmotility express antibodies against gona-
dotropin-releasing hormone in serum. Neurogastroenterol Motil 
2011;23:1000-1006, e459.
2. Hasler WL. Traditional thoughts on the pathophysiology of irritable 
bowel syndrome. Gastroenterol Clin North Am 2011;40:21-43.
3. Barbara G, Cremon C, Carini G, et al. The immune system in irrita-
ble blwel syndrome. J Neurogastroenterol Motil 2011;17:349-359.
4. Ohlsson B, Ekblad E, Veress B, Montgomery A, Janciauskiene S. 
Antibodies agonist gonadotropin-releasing hormone (GnRH) and 
destruction of enteric neurons in 3 patients suffering from gastro-
intestinal dysfunction. BMC Gastroenterol 2010;10:48-56.
5. Clarke G, Quigley EM, Cryan JF, Dinan TG. Irritable bowel syn-
drome: towards biomarker identification. Trends Mol Med 2009; 
15:478-489.
6. Hod K, Dickman R, Sperber A, et al. Assessment of high-sensitivity 
CRP as a marker of micro-inflammation in irritable bowel syndrome. 
Neurogastroenterol Motil 2011;23:1105-1110.
7. Törnblom H, Lang B, Clover L, Knowles CH, Vincent A, Lindberg 
G. Autoantibodies in patients with gut motility disorders and enteric 
neuropathy. Scand J Gastroenterol 2007;42:1289-1293.
8. Pittock SJ, Lennon VA, Dege CL, Tally NJ, Locke GR 3rd. Neural 
autoantibody evaluation in functional gastrointestinal disorders: a 
population-based case-control study. Dig Dis Sci 2011;56:1452- 
1459.
9. Lembo AJ, Neri B, Tolley J, Barken D, Carroll S, Pan H. Use of se-
rum biomarkers in a diagnostic test for irritable bowel syndrome. 
Aliment Pharmacol Ther 2009;29:834-842.
10. Ohlsson B, Veress B, Janciauskiene S, Montgomery A, Haglund M, 
Wallmark A. Chronic intestinal pseudo-obstruction due to buser-
elin-induced formation of anti-GnRH antibodies. Gastroenterology 
2007;132:45-51.
11. Khanna R, Browne RM, Heiner AD, Clench MH, Mathias JR. 
Leuprolide acetate affects intestinal motility in female rats before and 
after ovariectomy. Am J Physiol 1992;262(1 Pt 1):G185-G190.
12. Mathias JR, Baskin GS, Reeves-Darby VG, Clench MH, Smith 
LL, Calhoon JH. Chronic intestinal pseudoobstruction in a patient 
with heart-lung transplant. Therapeutic effect of leuprolide acetate. 
Dig Dis Sci 1992;37:1761-1768.
13. Klooker TK, Braak B, Koopman KE, et al. The mast cell stabilizer 
ketotifen decreases visceral hypersensitivity and improves intestinal 
symptoms in patients with irritable bowel syndrome. Gut 2010;59: 
1213-1221.